Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (trading symbol: AZYO) on June 8, 2022, regarding events occurring on June 7, 2022. The filing details the results of the Company's annual meeting of stockholders. The Company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting corporate governance voting results.
Material Changes and Voting Results
The primary event reported is the conclusion of the annual stockholder meeting. A total of 8,351,958 shares of Class A common stock were present or represented by proxy, representing approximately 89.74% of the outstanding common stock as of the April 13, 2022 record date. Two proposals were voted upon:
- Item 1: Election of Directors. Brigid A. Makes and C. Randal Mills were elected as Class II directors to serve until the 2025 annual meeting.
- Brigid A. Makes: 6,957,897 votes FOR; 268,128 votes WITHHELD; 1,125,933 Broker Non-Votes.
- C. Randal Mills: 6,957,160 votes FOR; 268,865 votes WITHHELD; 1,125,933 Broker Non-Votes.
- Item 2: Ratification of Auditors. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2022, was approved.
- Votes: 8,351,063 FOR; 850 AGAINST; 45 ABSTAINED; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting process. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the official appointment of Brigid A. Makes and C. Randal Mills to the Board of Directors.
- Confirm the engagement of PricewaterhouseCoopers LLP for the 2022 fiscal year audit.
- Review the Definitive Proxy Statement filed on April 22, 2022, for detailed background on the director nominees and auditor selection.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.